Home > Neurology > ECTRIMS 2019 > Optimising Long-Term Benefit of MS Treatment > Induction therapy over treatment escalation

Induction therapy over treatment escalation

Presented By
Prof. Alasdair Coles, Cambridge University Hospitals, United Kingdom
Conference
ECTRIMS 2019
Prof. Alasdair Coles (Cambridge University Hospitals, United Kingdom) discussed why induction therapy is the preferred principle over treatment escalation. “I have to admit that there is no perfect induction therapy in humans,” he mentioned at the beginning of his talk. The ideal induction therapy for an autoimmune disease is one “short sharp shock” of treatment with a restricted period of adverse effects, leading to long-lasting disease-specific immunological tolerance. This approach leaves the remaining immune system competent to fight infections and the patients free of infectious diseases risk. “How close are we to this ideal model in the management of MS?” Prof. Coles asked. “There are only 3 therapies which come close to what we might consider induction therapies of MS: autologous haematopoietic stem cell therapy (aHSCT), alemtuzumab, and cladribine. I want to make a point that not all high-efficacy therapies are induction therapies by the pro...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on